tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

BridgeBio Pharma Inc

BBIO
Add to Watchlist
84.030USD
+1.100+1.33%
Close 07-24 16:00（ET）Quotes delayed by 15 min
16.45BMarket Cap
LossP/E TTM

BridgeBio Pharma Inc

84.030
+1.100+1.33%
Overview
Financials
Discussions
Analysis
Company
Financial SummaryIncome StatementBalance SheetCash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial SummaryIncome StatementBalance SheetCash Flow Statement

BBIO Financials

See BridgeBio Pharma Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

BridgeBio Pharma Inc Earnings Date

Latest Release
May 7, 2026
EPS / Forecast
-0.84/-0.68
Revenue / Forecast
194.51M/177.94M
See Upcoming Earnings >>
Period
FY2025 Earnings
Revenue(YoY)
502.08M
126.26%
EPS(YoY)
-3.79
-31.46%
Analyst Rating
BUY
2026/07/24
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
Financial Indicators
EPS
4.36%-0.84
28.78%-1.00
-10.81%-0.95
-143.83%-0.95
-346.82%-0.88
-45.17%-1.40
20.69%-0.86
60.19%-0.39
78.54%-0.20
-4.61%-0.96
---1.08
---0.98
---0.92
---0.92
---2.34
----
----
----
----
----
Revenue
66.78%194.51M
2521.18%154.18M
4318.01%120.70M
4999.86%110.56M
-44.76%116.63M
237.08%5.88M
-33.22%2.73M
32.11%2.17M
11461.88%211.12M
-6.68%1.75M
1110.36%4.09M
-97.77%1.64M
7.79%1.83M
-85.49%1.87M
-85.58%338.00K
36.51%73.75M
266.67%1.69M
10462.30%12.89M
-71.16%2.34M
--54.02M
Net Profit
2.02%-164.04M
27.24%-192.86M
-12.78%-182.74M
-147.64%-181.90M
-375.41%-167.42M
-57.63%-265.05M
8.45%-162.04M
53.48%-73.46M
74.87%-35.22M
-22.21%-168.15M
-28.88%-177.00M
-1502.06%-157.90M
28.64%-140.16M
6.51%-137.59M
11.93%-137.34M
89.77%-9.86M
-20.43%-196.40M
-22.67%-147.18M
-34.59%-155.94M
20.40%-96.35M
Net Margin
41.12%-85.63%
97.22%-126.24%
97.45%-153.22%
95.23%-166.20%
-749.04%-145.42%
53.43%-4545.89%
-37.03%-6012.23%
64.42%-3484.50%
99.78%-17.13%
-29.85%-9760.92%
---4387.39%
---9792.99%
---7816.65%
---7517.11%
---454.07%
----
----
----
----
----
Gross Margin
-2.91%94.89%
46.73%94.74%
21.06%94.56%
33.53%96.70%
-1.99%97.74%
-1.77%64.57%
-8.52%78.11%
14.05%72.42%
54.96%99.72%
0.50%65.73%
--85.38%
--63.50%
--64.35%
--65.40%
--96.32%
----
----
----
----
----
Debt to assets ratio
-8.29%243.97%
20.85%289.26%
4.11%269.19%
14.04%246.58%
31.68%266.03%
-24.26%239.35%
-1.60%258.55%
-36.65%216.22%
-26.22%202.03%
15.31%316.03%
--262.76%
--341.29%
--273.83%
--274.08%
--233.10%
----
----
----
----
----
Income Statement
Revenue
66.78%194.51M
2521.18%154.18M
4318.01%120.70M
4999.86%110.56M
-44.76%116.63M
237.08%5.88M
-33.22%2.73M
32.11%2.17M
11461.88%211.12M
-6.68%1.75M
1110.36%4.09M
-97.77%1.64M
7.79%1.83M
-85.49%1.87M
-85.58%338.00K
36.51%73.75M
266.67%1.69M
10462.30%12.89M
-71.16%2.34M
--54.02M
Operating profit
-2.08%-105.96M
41.97%-128.43M
27.13%-136.36M
22.69%-133.47M
-2873.23%-103.80M
-25.29%-221.33M
-18.87%-187.13M
-21.10%-172.65M
103.05%3.74M
-45.35%-176.66M
-26.85%-157.42M
-98.62%-142.57M
18.69%-122.79M
26.61%-121.54M
16.99%-124.10M
23.65%-71.78M
9.84%-151.02M
-29.90%-165.61M
-24.65%-149.50M
24.53%-94.02M
Net Profit
2.02%-164.04M
27.24%-192.86M
-12.78%-182.74M
-147.64%-181.90M
-375.41%-167.42M
-57.63%-265.05M
8.45%-162.04M
53.48%-73.46M
74.87%-35.22M
-22.21%-168.15M
-28.88%-177.00M
-1502.06%-157.90M
28.64%-140.16M
6.51%-137.59M
11.93%-137.34M
89.77%-9.86M
-20.43%-196.40M
-22.67%-147.18M
-34.59%-155.94M
20.40%-96.35M
Balance Sheet
Current assets
78.56%1.24B
10.69%797.75M
88.80%839.38M
48.04%912.28M
-11.26%695.17M
50.90%720.69M
-24.35%444.58M
42.36%616.24M
41.74%783.42M
-12.98%477.59M
-8.49%587.67M
-43.87%432.88M
-22.83%552.70M
-38.25%548.85M
0.39%642.22M
-15.23%771.28M
-24.22%716.23M
38.27%888.86M
-14.18%639.71M
5.56%909.87M
Total current liabilities
436.72%816.37M
86.51%287.97M
55.59%216.60M
30.88%175.85M
7.51%152.10M
7.34%154.40M
31.26%139.22M
22.02%134.36M
46.46%141.48M
18.46%143.84M
-11.01%106.06M
-21.99%110.12M
-6.64%96.60M
-10.10%121.43M
24.39%119.19M
7.01%141.16M
9.22%103.46M
41.21%135.07M
26.57%95.82M
42.39%131.91M
Total assets
55.50%1.37B
1.82%936.02M
50.12%998.25M
35.98%1.08B
3.80%881.64M
68.26%919.34M
1.52%664.98M
57.72%794.38M
35.75%849.33M
-12.30%546.38M
-10.12%655.01M
-41.59%503.66M
-23.05%625.68M
-38.48%623.04M
-6.75%728.74M
-20.27%862.23M
-25.62%813.15M
43.95%1.01B
-0.78%781.52M
19.47%1.08B
Total liabilities
44.42%3.64B
26.74%3.01B
55.09%2.92B
52.34%2.86B
33.62%2.52B
25.84%2.38B
1.87%1.88B
1.25%1.88B
2.55%1.89B
1.12%1.89B
-0.56%1.85B
-1.28%1.85B
-0.78%1.84B
-0.55%1.87B
22.52%1.86B
22.13%1.88B
25.14%1.85B
215.32%1.88B
166.53%1.52B
166.07%1.54B
Total equity
-38.46%-2.27B
-42.46%-2.08B
-57.81%-1.92B
-64.35%-1.78B
-58.04%-1.64B
-8.57%-1.46B
-2.07%-1.22B
19.82%-1.08B
14.56%-1.04B
-7.84%-1.34B
-5.61%-1.19B
-32.97%-1.35B
-16.62%-1.21B
-43.83%-1.24B
-53.61%-1.13B
-122.77%-1.02B
-168.15%-1.04B
-902.31%-865.58M
-436.96%-735.87M
-239.12%-455.63M
Cash Flow Statement
Net operating income
0.98%-197.28M
71.11%-56.42M
39.32%-109.57M
-208.00%-80.68M
9.25%-199.24M
-56.49%-195.33M
-24.33%-180.57M
165.90%74.70M
-52.12%-219.54M
-33.86%-124.82M
-7.45%-145.23M
-272.22%-113.35M
10.16%-144.32M
30.36%-93.24M
-11.19%-135.16M
66.80%-30.45M
-6.55%-160.63M
-39.10%-133.90M
7.69%-121.56M
-4.40%-91.71M
Net investment
-2579.31%-42.73M
-343.44%-14.35M
-88.32%4.46M
-527.84%-13.00M
-107.01%-1.59M
-4804.55%-3.24M
1.44%38.23M
-26.22%3.04M
85.01%22.75M
-100.37%-66.00K
-74.34%37.68M
-97.25%4.12M
-91.13%12.30M
-17.59%17.96M
149.05%146.86M
32586.03%149.70M
149.15%138.62M
-73.74%21.80M
230.89%58.97M
100.36%458.00K
Net financing
811.50%549.89M
-100.46%-2.18M
-226.45%-894.00K
5372.14%302.04M
-78.42%60.33M
10578.24%473.93M
-99.77%707.00K
-365.39%-5.73M
86.06%279.55M
-170.93%-4.52M
21148.44%307.04M
94.08%-1.23M
94005.63%150.25M
-98.04%6.38M
101.07%1.45M
-1395.04%-20.80M
-100.03%-160.00K
7081.22%325.38M
-4969.02%-135.46M
-297.87%-1.39M

FAQs

What is the total revenue of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its total revenue reached 502.08M, with a year-on-year change of 221.90M.

What are the current assets of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its current assets were 797.75M, with a year-on-year change of 10.69.

What are the total assets of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its total assets of BridgeBio Pharma Inc were 936.02M, with a year-on-year change of 1.82.

What are the total liabilities of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its total liabilities of BridgeBio Pharma Inc were 3.01B, with a year-on-year change of 26.74.

What is the total equity of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its total equity of BridgeBio Pharma Inc was -2.08B, with a year-on-year change of -42.46.

What is the net operating income of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its net operating income of BridgeBio Pharma Inc was -502.06M, with a year-on-year change of 13.04.

What is the net investment of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its net investment of BridgeBio Pharma Inc was -24.49M, with a year-on-year change of -140.29.

What is the net financing of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its net financing of BridgeBio Pharma Inc was 359.29M, with a year-on-year change of -52.00.

What is the Earnings Per Share (EPS) of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -3.79, with a year-on-year change of -31.46.

What is the net income of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its net income was -724.93M, with a year-on-year change of -35.31.

What is the net margin of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its net profit margin was -145.98, with a year-on-year change of 40.38.

What is the gross margin of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its gross margin was 95.82, with a year-on-year change of -2.47.

What is the debt-to-asset ratio of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its debt-to-asset ratio was 289.26, with a year-on-year change of 20.85.

What is the Return on Assets (ROA) of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its Return on Assets (ROA) was -79.01, with a year-on-year change of -6.56.

What is the operating profit of BridgeBio Pharma Inc?

According to BridgeBio Pharma Inc's FY2025 earnings report, its operating profit was -502.06M, with a year-on-year change of 13.04.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy